Today's story
Novacyt H1 Loss Narrows, Revenue Rises 18%
Novacyt’s liquidity manager bought 44,200 shares and sold 44,422 in September, leaving 65,577 shares in treasury; the company has 72.6 million ordinary shares outstanding. For the first half of 2026, revenue rose 18% to £11.56 million and its net loss narrowed to £5.79 million from £6.34 million a year earlier.
Business · 11 sources · 2hRead itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Novacyt
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
Everything about Novacyt →- Country
- France
- Headquarters
- Vélizy-Villacoublay, Le Vésinet
- Inception
- July 3, 2006
- Website
- https://novacyt.com/